一个新的弱监督的深度神经网络用于识别阿尔茨海默病的疾病
Xiaobo Zhang1, Zhimin Li2, Qian Zhang3
1School of Computing and Artificial Intelligence, SouthWest JiaoTong University, Chengdu 611756, China; Engineering Research Center of Sustainable Urban Intelligent Transportation, Ministry of Education, Chengdu 611756, China; National Engineering Laboratory of Integrated Transportation Big Data Application Technology, Southwest Jiaotong University, Chengdu 611756, China.
Computers in biology and medicine
|June 15, 2023
概括
一种新的弱监督深度学习 (WSDL) 模型使用未标记的大脑MRI数据改进了阿尔茨海默病 (AD) 诊断. 这种方法有效地利用现有的医疗数据,即使缺少标签,以提高诊断准确度.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 人工智能的人工智能
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,主要影响老年人的认知和记忆.
- 机器学习有助于诊断AD,但监督的方法与低质量或未标记的医疗数据作斗争.
- 与标记大型医疗数据集相关的高成本限制了传统监督学习的应用.
研究的目的:
- 为阿尔茨海默病诊断提出一个弱监督深度学习 (WSDL) 模型.
- 为了应对在AD预测中未标记和低质量的医疗数据所带来的挑战.
- 提高广泛的未标记的医疗数据集的利用,以提高诊断准确度.
主要方法:
- 开发了一个WSDL模型,在EfficientNet框架内整合了注意力机制和一致性规范化.
- 采用数据增强技术来最大限度地利用未标记的数据.
- 在阿尔茨海默氏病神经成像计划 (ADNI) 脑MRI数据集上验证了WSDL模型,具有不同的未标记数据比率.
主要成果:
- 拟议的WSDL方法在阿尔茨海默氏症诊断中表现优于基线方法.
- 实验结果证实了该模型在不同比例的未标记数据中的有效性.
- WSDL方法成功地利用未标记的大脑MRI数据进行强大的AD预测.
结论:
- WSDL模型为阿尔茨海默病诊断提供了一个有希望的解决方案,特别是在处理有限的标记数据时.
- 这种方法有效地利用未标记的医学成像数据,减少对昂贵的手动标签的依赖.
- 这些发现突显了弱监督学习在推进神经退行性疾病诊断方面的潜力.
相关概念视频
Alzheimer's Disease: Overview
532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223
Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
Dementia
143
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
143


